RLYB - חוב כולל להון Rallybio

Rallybio Corporation (RLYB) bases its competitive advantage on patent law and the exclusivity of orphan drugs. This price chart on the GURU.Markets platform shows that the individual debt-to-equity ratio is 0.00. Rallybio Corporation (RLYB) develops innovative antibodies through partnerships with global laboratories to treat blood incompatibility. Business growth is driven by the success of the FNAIT program, a significant liquidity reserve, and a focus on high-cost drugs for rare pathologies.

Identifying fundamentally resilient assets requires analyzing the balance sheet structure via the total liabilities-to-equity ratio, which determines the business's degree of dependence on borrowed funds. Low financial leverage, as reflected in the total debt-to-equity ratio, confirms the ability of Rallybio Corporation (RLYB) to finance robotic automation for rare disease research without a critical debt burden, thereby reducing default risks amid fluctuating interest rates.